In a report released today, Andrew Berens from Leerink Partners maintained a Buy rating on BeiGene, with a price target of $414.00. The company’s shares closed last Wednesday at $356.41.
According to TipRanks.com, Berens is a 4-star analyst with an average return of 6.7% and a 60.8% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Deciphera Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BeiGene with a $417.33 average price target.
Dyne Therapeutics (DYN)
Jefferies analyst Eun Yang maintained a Buy rating on Dyne Therapeutics yesterday and set a price target of $47.00. The company’s shares closed last Wednesday at $14.88, close to its 52-week low of $13.50.
According to TipRanks.com, Yang is a 4-star analyst with an average return of 7.6% and a 50.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Aerovate Therapeutics, and Taysha Gene Therapies.
Currently, the analyst consensus on Dyne Therapeutics is a Moderate Buy with an average price target of $40.50, representing a 173.5% upside. In a report issued on October 1, Piper Sandler also maintained a Buy rating on the stock with a $34.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.